General Information of Drug Therapeutic Target (DTT) (ID: TT6TLZP)

DTT Name Aspartoacylase (ASPA)
Synonyms Aminoacylase-2; ACY-2
Gene Name ASPA
DTT Type
Clinical trial target
[1]
UniProt ID
ACY2_HUMAN
TTD ID
T63188
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 3.5.1.15
Sequence
MTSCHIAEEHIQKVAIFGGTHGNELTGVFLVKHWLENGAEIQRTGLEVKPFITNPRAVKK
CTRYIDCDLNRIFDLENLGKKMSEDLPYEVRRAQEINHLFGPKDSEDSYDIIFDLHNTTS
NMGCTLILEDSRNNFLIQMFHYIKTSLAPLPCYVYLIEHPSLKYATTRSIAKYPVGIEVG
PQPQGVLRADILDQMRKMIKHALDFIHHFNEGKEFPPCAIEVYKIIEKVDYPRDENGEIA
AIIHPNLQDQDWKPLHPGDPMFLTLDGKTIPLGGDCTVYPVFVNEAAYYEKKEAFAKTTK
LTLNAKSIRCCLH
Function
Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate. NAA occurs in high concentration in brain and its hydrolysis NAA plays a significant part in the maintenance of intact white matter. In other tissues it acts as a scavenger of NAA from body fluids.
KEGG Pathway
443 (hsa )
Reactome Pathway
( )
(R-HSA-8963693 )
BioCyc Pathway
MetaCyc:HS03094-MONOMER

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
BBP-812 DM9PSZ1 Canavan disease 5C50.E1 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of Adrenas Therapeutics